1. Home
  2. BOLD vs NTIP Comparison

BOLD vs NTIP Comparison

Compare BOLD & NTIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BOLD
  • NTIP
  • Stock Information
  • Founded
  • BOLD 2018
  • NTIP 1990
  • Country
  • BOLD United States
  • NTIP United States
  • Employees
  • BOLD N/A
  • NTIP N/A
  • Industry
  • BOLD
  • NTIP Multi-Sector Companies
  • Sector
  • BOLD
  • NTIP Miscellaneous
  • Exchange
  • BOLD Nasdaq
  • NTIP Nasdaq
  • Market Cap
  • BOLD 33.4M
  • NTIP 32.0M
  • IPO Year
  • BOLD 2024
  • NTIP 1998
  • Fundamental
  • Price
  • BOLD $1.15
  • NTIP $1.49
  • Analyst Decision
  • BOLD Buy
  • NTIP
  • Analyst Count
  • BOLD 4
  • NTIP 0
  • Target Price
  • BOLD $4.00
  • NTIP N/A
  • AVG Volume (30 Days)
  • BOLD 85.6K
  • NTIP 5.7K
  • Earning Date
  • BOLD 11-05-2025
  • NTIP 11-06-2025
  • Dividend Yield
  • BOLD N/A
  • NTIP 6.90%
  • EPS Growth
  • BOLD N/A
  • NTIP N/A
  • EPS
  • BOLD N/A
  • NTIP N/A
  • Revenue
  • BOLD N/A
  • NTIP $150,000.00
  • Revenue This Year
  • BOLD N/A
  • NTIP N/A
  • Revenue Next Year
  • BOLD N/A
  • NTIP N/A
  • P/E Ratio
  • BOLD N/A
  • NTIP N/A
  • Revenue Growth
  • BOLD N/A
  • NTIP N/A
  • 52 Week Low
  • BOLD $1.00
  • NTIP $1.16
  • 52 Week High
  • BOLD $3.54
  • NTIP $1.90
  • Technical
  • Relative Strength Index (RSI)
  • BOLD 39.64
  • NTIP 48.18
  • Support Level
  • BOLD $1.17
  • NTIP $1.30
  • Resistance Level
  • BOLD $1.18
  • NTIP $1.48
  • Average True Range (ATR)
  • BOLD 0.07
  • NTIP 0.06
  • MACD
  • BOLD -0.01
  • NTIP -0.01
  • Stochastic Oscillator
  • BOLD 51.79
  • NTIP 65.22

About BOLD Boundless Bio Inc. Common Stock

Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

About NTIP Network-1 Technologies Inc.

Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.

Share on Social Networks: